Drugs treatment of pain in multiple sclerosis

Current Clinical Pharmacology

Volumn 2, Issue 3, 2007, Pages 227-233

  Siniscalchi, Antonio ^a   Gallelli, Luca ^b   De Sarro, Giovambattista ^b  

^a ANNUNZIATA HOSPITAL   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BACLOFEN; BENZODIAZEPINE; CARBAMAZEPINE; CORTICOTROPIN; DANTROLENE; FLUPHENAZINE; GABAPENTIN; LAMOTRIGINE; LORAZEPAM; MAPROTILINE; METHYLPREDNISOLONE; MEXILETINE; MISOPROSTOL; MORPHINE; MUSCLE RELAXANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OXCARBAZEPINE; PARACETAMOL; PHENYTOIN; PLACEBO; PREDNISOLONE; STEROID; TIZANIDINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

AGRANULOCYTOSIS; ATAXIA; BACKACHE; BONE DENSITY; CHRONIC PAIN; CLINICAL TRIAL; COARSE FACE; COGNITIVE DEFECT; DISABILITY; DISEASE CLASSIFICATION; DIZZINESS; DROWSINESS; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EMOTIONAL DISORDER; FATIGUE; GINGIVA HYPERPLASIA; GLOSSOPHARYNGEAL NEURALGIA; HIRSUTISM; HUMAN; HYPONATREMIA; LEUKOPENIA; LHERMITTE DUCLOS DISEASE; MENORRHAGIA; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; NAUSEA; NERVE ROOT COMPRESSION; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; OPTIC NEURITIS; ORTHOSTATIC HYPOTENSION; PAIN; PARESTHESIA; PATHOPHYSIOLOGY; PATIENT CARE; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; QT INTERVAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SOMNOLENCE; TRIGEMINUS NEURALGIA; VISCERAL PAIN; WEIGHT GAIN;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; HUMANS; MULTIPLE SCLEROSIS; PAIN;

EID: 34948856388     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488407781668785     Document Type: Review

References (89)

1. Boivie J. Central pain. In: Wall PD, Melzack R, editors. Textbook of Pain, 4th edition. New York: Churchill Livingstone. 1999: 879-914.
2. Crayton H, Heyman RA, Rossman HS. A multimodal approach to managing the symptoms of multiple sclerosis. Neurology 2004; 63: S12-8.
3. Svendsen KB, Jensen TS, Overvad K, Hansen HJ, Koch-Henriksen N, Bach FW. Pain in patients with multiple sclerosis: a population-based study. Arch Neurol 2003; 60: 1089-94.
4. Archibald CJ, McGrath PJ, Ritvo PG, et al. Pain prevalence, severity and impact in a clinic sample of multiple sclerosis patients. Pain 1994; 58: 89-93.
5. Kalia LV, O'Connor PW. Severity of chronic pain and its relationship to quality of life in multiple sclerosis. Mult Scler 2005; 11: 322-7.
6. Krupp LB, Rizvi SA. Symptomatic therapy for underrecognized manifestations of multiple sclerosis. Neurology 2002; 58(suppl 4): S32-9.
7. Chatel M, Lanteri-Minet M, Lebrun-Frenay C. Pain in multiple sclerosis. Rev Neurol 2001; 157: 1072-8.
8. Solaro C, Lunardi GL, Mancardi GL. Pain and MS. Int MS J 2003; 10: 14-9.
9. Groves L, Shellenberger MK, Davis CS. Tizanidine tretmnet of spasticity:a meta-analysis of controlled, double-blind, comparative studies wit baclofen and diazepam. Adv Ther 1998; 15(4): 241-51.
10. Solaro C, Uccelli MM, Guglieri P, Uccelli A, Mancardi Gl. Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis. Mult Scler 2000; 6: 192-3.
11. Osterberg A, Boivie J, Thuomas KA. Central pain in multiple sclerosis - prevalence and clinical characteristics. Eur J Pain 2005; 9: 531-42.
12. Garcin R. Thalamic syndrome and pain of central origin. In: Soulairac A, Cahn J, Charpentier J, editors. Pain. London: Academic Press. 1968; 421-541.
13. Craig AD. A new version of the thalamic disinhibition hypothesis of central pain. Pain Forum 1998; 7: 1-14.
14. Smith KJ, McDonald WI. The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease. Phil Trans R Soc Lond B 1999; 354: 1649-73.
15. Hooge JP, Redekop WK. Trigeminal neuralgia in multiple sclerosis. Neurology 1995; 45: 1294-6.
16. Miro J, Garcia-Monco C, Leno C, Berciano J. Pelvic pain: an undescribed paroxysmal manifestation of multiple sclerosis. Pain 1988; 32: 73-5.
17. Craner MJ, Damarjian TG, Liu S, et al. Sodium channels contribute to microglia/macrophage activation and function in EAE and MS. Glia 2005;49: 220-9.
18. Solaro C, Brighetto G, Battaglia MA, Uccelli MM, Mancardi GL. Antiepileptic medications in multiple sclerosis: adverse effects in a three-year follow-up study. Neurol Sci 2005; 25: 307-10.
19. Hawker K, Frohman E, Racke M. Levetiracetam for phasic spasticity in multiple sclerosis. Arch Neurol 2003; 60: 1772-4.
20. Solaro C, Taganelli P. Tiagabine for treating painful tonic spasms in multiple sclerosis. A pilot study. J Neurol Neurosurg Psychiatry 2004; 75: 341.
21. Minagar A, Sheremata WA. Glossopharyngeal neuralgia and MS. Neurology 2000; 54: 1368-70.
22. Kuroiwa Y. Shibasaki H. Painful tonic seizure in multiple sclerosís treatment with diphenylhydantoin and carbamazepine. Folia Psychiatr Neurol Jpn 1968; 22: 107-19.
23. Cambier J, Dehen H. Les douleurs fulgurantes. Etiologie et physiopathologies. Nouv Presse Med 1971; 79: 1419.
24. Portenoy RK, Yang K, Thorton D. Chronic intractable pain: an atypical presentation of multiple sclerosis. J Neurol 1988; 235: 226-8.
25. Ramsaransing G, Zwanikken C, De Keyser J. Worsening of symptoms of multiple sclerosis associated with carbamazepine. BMJ 2000; 320: 1113.
26. Beydoun A, Kobetz SA, Carrazana EJ. Efficacy of oxcarbazepine in the treatment of painful diabetic neuropathy. Clin J Pain 2004; 20: 174-8.
27. Mclean MJ, MacDonald. RL. Multiple actions of phenytoin on mouse spinal cord neurons in cell culture. J Pharmacol Exp Ther 1983; 227: 779-89.
28. Narahashi T. Drugs acting on calcium channels. Handbk Exp Pharmacol 1988; 83: 255-74.
29. Yaari Y, Selzer ME, Pincus JH. Phenytoin: mechanism of its anti-convulsive action. Ann Neurol 1986; 20: 171-84.
30. Swerdlow M. Anticonvulsant drugs and chronic pain. Clin Neuropharmacol 1984; 7: 51-82.
31. Kuroiwa Y, Shibasaki H. Painful tonic seizure in multiple sclerosís treatment with diphenylhydantoin and carbamazepine. Folia Psychiatr Neurol Jpn 1968; 22: 107-19.
32. Glifford DB, Trotter IL. Pain in multiple sclerosis. Arch Neurol 1984; 41: 1270-2.
33. Taylor CP, Gee NS, Su TZ, et al. A summary of mechanistic hypothesis of gabapentin pharmacology. Epilepsy Res 1998; 29: 233-49.
34. Solaro C, Lunardi GL, Capello E, et al. An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. Neurology 1998; 51: 609-11.
35. Houtchens MK, Richert JR, Sarni A, Rose, JW. Open label gabapentin treatment for pain in multiple scierosis. Mult Scler 1997; 3: 250-3.
36. Khan OA. Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients. Neurology 1998; 51: 611-4.
37. Cutter NC, Scott DD, Johnson JC, et al. Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. Arch Phys Med Rehabil 2000; 81: 164-9.
38. Solaro C, Messmer Uccelli M, Uccelli A, Leandri M, Mancardì GL. Low-dose gabapentin combìned with either lamotrigine or carbamazepine can be useful therapies for trigeminal neuralgia in multiple sclerosis. Eur Neurol 2000; 44: 45-8.
39. Samkoff LM, Daras M, Tuchman AI, Koppel BS. Amelioratíon of refractory dysesthetic limb pain in multiple sclerosis by gabapentin. Neurology 1997; 49: 304-5.
40. Colombo B, Annovazzi POL, Comi G. Medications for neuropathic pain: current trends. Neurol Sci 2006; 27: S183-9.
41. Cianchetti C, Zuddas A, Randazzo AP, Perra L, Marrosu MG. Lamotrìgine adjunctive therapy in painful phenomena in MS: preliminary observations. Neurology 1999; 53: 433.
42. McCleane G. Lamotrigine can reduce neurogenic pain associated with multiple sclerosis. Clin J Pain 1998; 14: 269-70.
43. Lunardi G, Leandri M, Albano G, et al. Clinical effectiveness of lamotrigine and plasma levels in essential and symptomatic trigeminal neuralgia. Neurology 1997; 48: 1714-17.
44. Leandri M, Lundardi G, Inglese M, et al. Lamotrigine in trigeminal neuralgia secondary to multiple sclerosis. J Neurol 2000; 247: 556-8.
45. Guberman AH, Besag FM, Brodie MJ, et al. Lamotrigine associated rash: risk/benefit consideration in adults and children. Epilepsia 1999; 40: 985-91.
46. Russo E, Constanti A, Ferreri G, Citrato R, De Sarro G. Nifedipine affects the anticonvulsant activity of topiramate in various animal models of epilepsy. Neuropharmacology 2004; 46: 865-78.
47. Zvartau-Hind M, Din MU, Gilani A, Lisak RP, Khan OA. Topiramate relieves refractory trigeminal neuralgia in MS patients. Neurology 2000; 55: 1587-8.
48. Siniscalchi A, Gallelli L, Scornaienghi D, Mancuso F, De Sarro G. Topiramate therapy for symptomatic trigeminal nevralgia. Clin Drug Invest 2006; 26(2): 113-5.
49. Watson CP, Evans RJ, Reed K, Merskey H, Goldsmith L, Warsh J. Amitriptyline versus placebo in postherpetic neuralgia. Neurology 1982; 32: 671-3.
50. Rowbotham MC, Reisner LA, Davies PS, Fields HL. Treatment response in antidepressant-naïve postherpetic neuralgia patient: double-blid randomized trial. J Pain 2005; 6: 741-6.
51. Sindrup SH, Otto M, Finnerup NB, Jensen TS. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol 2005; 96: 399-409.
52. Max MB, Schafer SC, Culnane M, Smoller B, Dubner R, Gracely RH. Amitriptyline but not lorazepam relieves postherpetic neuralgia. Neurology 1988; 38: 1427-32.
53. Graff-Radford SB, Shaw LR, Naliboff BN. Amitriptyline and fluphenazine in the treatment of postherpetic neuralgia. Clin J Pain 2000; 16: 188-92.
54. Sindrup SH, Jensen TS. Pharmacologic treatment of pain in polyneuropathy. Neurology 2000; 55: 915-20.
55. Clifford DB, Trotter IL. Pain in multiple sclerosis. Arch Neerol 1984; 41: 1270-2.
56. Moulin DE. Pain in central and peripheral demyelinating disorders. Neurol Clin 1998; 16: 889-98.
57. Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group [see comments]. N Engl J Med 1992; 326: 581-8.
58. Sachais BA, Logue JN, Carey MS. Baclofen, a new antispastic drug. A controlled, multicenter trial in patients with multiple sclerosis. Arch Neurol 1977; 34: 422-8.
59. Herman RM, D'Luzansky SC, Ippolito R. Intrathecal baclofen suppresses central pain in patients with spinal lesions. A pilot study. Clin J Pain 1992; 8: 338-45.
60. Becker R, Uhle EI, Alberti O, Bertalanffy H. Continuous intrathecal baclofen infusion in the management of central deafferentation pain. J Pain Symptom Manage 2000; 20: 313-15.
61. Boviatsis EJ, Kouyialis AT, Korfias S, Sakes DE. Functional outcome of intrathecal baclofen administration for severe spasticity. Clin Neurol Neurosurg 2005; 107: 289-95.
62. Ben Smail D, Peskine A, Roche N, Mailhan L, Thiebaut I, Bussel B. Intrathecal baclofen for treatment of spasticity of multiple sclerosis patients. Mult Scler 2006; 12: 101-3.
63. Davies WL, Grunert RR, Haff RF, et al. Antiviral activity of 1-adamantanamine (amantadine). Science 1964; 144: 862-3.
64. Blanchet PJ, Metman LV, Chase TN. Renaissance of amantadine in the treatment of Parkinson's disease. Adv Neurol 2003; 91: 251-7.
65. Fisher K, Coderre TJ, Hagen NA.. Targeting the N-methyl-D-aspartate receptor for chronic pain management. Preclinical animal studies, recent clinical experience and future research directions. J Pain Symptom Manage 2000; 20: 358-73.
66. Hay AJ. The action of adamantanamines against influenza A viruses: inhibition of the M2 ion channel protein. Semin Virol 1992; 3: 21-30.
67. Snow BJ, Macdonald L, Mcauley D, Wallis W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double blind, placebo-controlled study. Clin Neuropharmacol 2000; 23: 82-5.
68. Verhagen Metman L, Del Dotto P, van den Munckhof BS, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998; 50: 1323-6.
69. Blanpied TA, Clarke RJ, Johnson JW. Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J Neurosci 2005; 25: 3312-22.
70. Chiba S, Ito M, Matsumoto H. Amantadine treatment for refractory pain and fatigue in patients with multiple sclerosis. Can J Neurol Sci 1992; 19: 309.
71. Reder AT, Arnason BG. Trigeminal neuralgia in multiple sclerosis relieved by a prostaglandin E analogue. Neurology 1995; 45: 1097-100.
72. Lüttmann R, Brinkmann B, Frese A, Loddenkemper T, Husstedt IW, Evers S. Misoprostol in the treatment of trigeminal neuralgia in MS patients: a report of three cases. Cephalalgia 2000; 20: 382.
73. DMKG study group. Misoprostol in the treatment of trigeminal neuralgia associated with multiple sclerosis. J Neurol 2003; 250: 542-5.
74. Paíce,JA, Penn RD, Kroin JS. Intrathecal octreotide for relief of intractable nonmalignant pain: 5-year experience with two cases. Neurosurgery 1996; 38: 203-7.
75. Dahm PO, Nitescu PV, Appelgren LK, Curelaru I. Long-term intrathecal (i.t.) infusion of bupivacaine relieved intractable pain and spasticity in a patient with multiple sclerosis. Eur J Pain 1998; 2: 81-5.
76. Sethi KD, Hess DC, Huffnagle VH, Adams RJ. Acetazolamide treatment of paroxysmal dystonia in central demyelinating disease. Neurology 1992; 42: 919-21.
77. Voiculescu V, Pruskauer-Apostol B, Alecu C. Treatment with acetazolamide of brain-stem and spinal paroxysmal disturbances in multiple sclerosis. J Neurol Neurosurg Psychiatry 1975; 38: 191-3.
78. Kalman S, Osterberg A, Sorensen J, Boivie J, Bertler A. Morphine responsiveness in a group of well-defined multiple sclerosis patients: a study with i.v. morphine. Eur J Pain 2002; 6: 69-82.
79. Gallantine EL, Meert TF. A comparison of the antinociceptive and adverse effects of the mu-opioid agonist morphine and the delta-opioid agonist SNC80. Basic Clin Pharmacol Toxicol 2005; 97: 39-51.
80. Sakuraí M, Kanazawa I. Positive symptoms in multiple sclerosis: their treatment with sodium channel blockers, lidocaine and mexíletine. J Neurol Sci 1999; 162: 162-8.
81. Awerbuch GI, Sandyk R. Mexiletine for thalamic pain syndrome. Int J Neurosci 1990; 55: 129-33.
82. Perras C. Sativex for the management of multiple sclerosis symptoms. Issue Emerg Healt Technol 2005; 72: 1-4.
83. Alsasua Del Valle A. Implication of cannabinoids in neurological diseases. Cell Mol Neurobiol 2006; 26(4-6): 579-91.
84. Killestein J, Uitdehaag BM, Polman CH. Cannabinoids in multiple sclerosis: do they have a therapeutic role? Drugs 2004; 64(1): 1-11.
85. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomized double blind placebo controlled crossover trial. BMJ 2004; 329: 253-57.
86. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005; 65: 812-9.
87. Azad SC, Rammes G. Cannabinoids in anaesthesia and pain therapy. Curr Opin Anaesthesiol 2005; 18: 424-7.
88. Trebst C, Stangel M. Cannabinoids in multiple sclerosis - therapeutically reasonable? Fortschr Neurol Psychiatr 2005; 73: 463-9.
89. Barnes MP. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opin Pharmacother 2006; 7: 607-1.